Boston, MA 07/26/2013 (wallstreetpr) – Boston Scientific Corporation (NYSE:BSX) has received the clearance from US Food and Drug Administration for Rhythmia Mapping System which is used in the diagnosis and treatment of a variety of conditions for the abnormal heart beats. Boston Scientific offers this Rhythmia Mapping System along with 64-electrode mapping catheter of high resolution. This catheter has also received the FDA clearance. This mapping system is a next generation three dimensional solution for mapping and navigation for the purpose of cardiac catheter ablations and many other electrophysiology procedures. Per Warren Jackman, University of Oklahoma Health Sciences Center, this system is believed to become the gold standard for the mapping as well as the navigation. This is because the system delivers the maps in good clarity.
The Boston Scientific Corporation has also received the clearance for the approval of the company’s OptiCross, which is a catheter that is developed for coronary imaging. This has been launched in US and Europe and the launch in Japan is planned in this month. The OptiCross is the intravascular ultrasound catheter which offers the imaging of high resolution and facilitating the complex procedures in the coronary.
During the last trading session, Boston Scientific Corporation reported the profit of second quarter. This profit has surpassed the expectations and the forecast growth on the sales of the company’s devices and products. During the early trading, the shares of Boston Scientific Corporation increased by 9.1% to reach $ 10.49. During the afternoon trading, the stock of the company rose 11% or $ 1.03 to reach $ 10.64.
The company reported a net income of $ 130 million or in other words 10 cents for each share in comparison with $ 2.51 for each share $ or a net loss of 3.58 billion during the last year. The company is projected to earn between 14 cents and 16 cents for each share during the third quarter.
